0.2384
price up icon0.34%   0.0003
 
loading
Scisparc Ltd stock is traded at $0.2384, with a volume of 37,112. It is up +0.34% in the last 24 hours and down -17.62% over the past month. SciSparc Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The company has two reportable segments; development of drugs based on cannabinoid molecules to be approved by an official regulatory authority (the company's operation); and online sales of a various range of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States.
See More
Previous Close:
$0.2381
Open:
$0.2381
24h Volume:
37,112
Relative Volume:
0.03
Market Cap:
$2.47M
Revenue:
$2.88M
Net Income/Loss:
$-5.12M
P/E Ratio:
-0.000883
EPS:
-269.9888
Net Cash Flow:
-
1W Performance:
+3.46%
1M Performance:
-17.62%
6M Performance:
-79.75%
1Y Performance:
-96.25%
1-Day Range:
Value
$0.234
$0.2449
1-Week Range:
Value
$0.2125
$0.2449
52-Week Range:
Value
$0.2055
$14.22

Scisparc Ltd Stock (SPRC) Company Profile

Name
Name
Scisparc Ltd
Name
Phone
-
Name
Address
-
Name
Employee
3
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SPRC's Discussions on Twitter

Compare SPRC with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
SPRC 0.2389 2.47M 2.88M -5.12M 0 -269.99
VRTX 446.08 115.74B 10.63B -479.80M -1.35B 13.33
REGN 740.77 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 589.60 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.12 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 102.86 24.49B 3.30B -501.07M 1.03B 11.54

Scisparc Ltd Stock (SPRC) Latest News

pulisher
Nov 04, 2024

SciSparc Ltd. Reports Changes in Financial Position - TipRanks

Nov 04, 2024
pulisher
Nov 04, 2024

SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com

Nov 04, 2024
pulisher
Oct 23, 2024

SciSparc Ltd. Gains Shareholder Approval for Proposals - TipRanks

Oct 23, 2024
pulisher
Oct 22, 2024

SciSparc Ltd. Reschedules Annual General Meeting - TipRanks

Oct 22, 2024
pulisher
Oct 16, 2024

Examining SPRC’s book value per share for the latest quarter - US Post News

Oct 16, 2024
pulisher
Oct 16, 2024

Financial Metrics Unveiled: SciSparc Ltd (SPRC)’s Key Ratios in the Spotlight - The Dwinnex

Oct 16, 2024
pulisher
Oct 09, 2024

SPRC Stock Hits 52-Week Low at $0.21 Amid Market Challenges - Investing.com

Oct 09, 2024
pulisher
Oct 08, 2024

SciSparc gains as Clearmind partnership yields 3 new international patent applications - MSN

Oct 08, 2024
pulisher
Oct 01, 2024

SciSparc stock plunges to 52-week low, hits $0.23 - Investing.com India

Oct 01, 2024
pulisher
Oct 01, 2024

Pharma Company Gets FDA Green Light For Next Phase Trial For Tourette Syndrome - 420 Intel

Oct 01, 2024
pulisher
Oct 01, 2024

SciSparc receives FDA approval for trial for Tourette syndrome therapy - Clinical Trials Arena

Oct 01, 2024
pulisher
Oct 01, 2024

SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN

Oct 01, 2024
pulisher
Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study By Investing.com - Investing.com South Africa

Sep 30, 2024
pulisher
Sep 30, 2024

Pharmaceutical FDA Next Phase Cannabinoid For TouretteSciSparc (NASDAQ:SPRC) - Benzinga

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc secures FDA approval to launch Phase IIB trial for TS treatment - TipRanks

Sep 30, 2024
pulisher
Sep 30, 2024

FDA greenlights SciSparc's Phase IIb Tourette Syndrome study - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its - GlobeNewswire

Sep 30, 2024
pulisher
Sep 30, 2024

Financial Metrics Check: SciSparc Ltd (SPRC)’s Ratios for Trailing Twelve Months - The Dwinnex

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment - StockTitan

Sep 30, 2024
pulisher
Sep 30, 2024

SciSparc Ltd (SPRC) stock: A year of ups and downs - US Post News

Sep 30, 2024
pulisher
Sep 29, 2024

SciSparc signs LOI to sell entire ownership in MitoCareX - MSN

Sep 29, 2024
pulisher
Sep 27, 2024

SciSparc Ltd. Proposes Reverse Stock Split - TipRanks

Sep 27, 2024
pulisher
Sep 26, 2024

SciSparc plans to sell MitoCareX stake for enhanced valuation By Investing.com - Investing.com Canada

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc plans to sell MitoCareX stake for enhanced valuation - Investing.com

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc Announces Intent to Sell MitoCareX Stake - TipRanks

Sep 26, 2024
pulisher
Sep 26, 2024

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX - GlobeNewswire

Sep 26, 2024
pulisher
Sep 25, 2024

Holdings of SciSparc Ltd (SPRC) are aligned with the stars - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3% - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Smartgroup Announces Major Shareholding Changes - TipRanks

Sep 25, 2024
pulisher
Sep 25, 2024

Science Group PLC Executes Share Buyback - TipRanks

Sep 25, 2024
pulisher
Sep 24, 2024

Site Group Plans Massive New Share Issue - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Spyre Therapeutics (NASDAQ:SYRE) Stock Price Down 4.1% - Defense World

Sep 24, 2024
pulisher
Sep 24, 2024

Recent Insider Activity Suggests Potential Gains for Spruce Biosciences Inc (SPRB) - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

SIGA Technologies (NASDAQ:SIGA) Shares Down 2.4% - MarketBeat

Sep 24, 2024
pulisher
Sep 24, 2024

CSG urges Vista Outdoor stockholders to vote for $2.15B Kinetic Group deal - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

Smiths Group results: Could the share price sell-off present an opportunity? - Investors Chronicle

Sep 24, 2024
pulisher
Sep 24, 2024

SThree Q3 net fees slip 8% amid challenging conditions - Staffing Industry Analysts

Sep 24, 2024
pulisher
Sep 24, 2024

Clearmind, SciSparc slide amid weight-loss study results - MSN

Sep 24, 2024
pulisher
Sep 24, 2024

FINANCIALS: SThree reports 8% drop due to challenging conditions - Recruiter

Sep 24, 2024
pulisher
Sep 24, 2024

UBS Cuts Stake in Spirent Communications - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree maintains expectations amid tough market conditions. - Research the market

Sep 24, 2024
pulisher
Sep 24, 2024

UK recruiter SThree falls on lower Q3 net fee - XM

Sep 24, 2024
pulisher
Sep 24, 2024

SThree says UK the worst performer as recruitment fees drop - Proactive Investors UK

Sep 24, 2024
pulisher
Sep 24, 2024

Science Group PLC Announces Share Buyback - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree plc Navigates Market Headwinds in Q3 - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

SThree Net Fees Fall Amid Challenging Environment - MarketWatch

Sep 24, 2024
pulisher
Sep 24, 2024

Recruiter SThree holds guidance despite ‘challenging’ market conditions - City A.M.

Sep 24, 2024
pulisher
Sep 23, 2024

100,000 Shares in Spyre Therapeutics, Inc. (NASDAQ:SYRE) Purchased by Integral Health Asset Management LLC - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

SciSparc Ltd Inc. (SPRC) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Sep 23, 2024
pulisher
Sep 23, 2024

Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Down to $30.17 - MarketBeat

Sep 23, 2024
pulisher
Sep 23, 2024

Financial Survey: ScripsAmerica (OTCMKTS:SCRCQ) versus Cosmos Health (NASDAQ:COSM) - Defense World

Sep 23, 2024

Scisparc Ltd Stock (SPRC) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):